Bone health & osteoporosis

What changes during this transition

Osteoporosis is one of the few axes where 'peptides for this condition' is a genuine positive case in approved medicine — not community extrapolation. Teriparatide (Forteo, PTH 1-34) and abaloparatide (Tymlos, PTHrP analog) are both peptides, both FDA-approved, and both anchor the anabolic side of severe osteoporosis treatment with fracture-reduction RCT data. Romosozumab (Evenity, anti-sclerostin antibody, FDA 2019) outperformed alendronate in the ARCH trial. Juno's library doesn't currently stock teriparatide or abaloparatide, and that gap matters: the strongest anti-fracture peptide medicine sits outside this catalog, and any user landing here for osteoporosis guidance deserves to hear that first. The standard-of-care framework starts with DEXA T-score staging (osteopenia -1.0 to -2.5, osteoporosis at or below -2.5) and FRAX 10-year fracture risk. Foundational interventions — 1000-1200 mg calcium, 800-1000 IU vitamin D3, weight-bearing exercise, adequate protein, smoking and alcohol cessation, and addressing secondary causes (hyperparathyroidism, celiac, hyperthyroidism, myeloma, vitamin D deficiency, hypogonadism) — come before any pharmacotherapy. First-line antiresorptives are alendronate 70 mg weekly oral (cheap, Tier 1 fracture-reduction from FIT and FLEX trials) and zoledronic acid 5 mg IV annually (Tier 1 from HORIZON). Denosumab (Prolia) is the SubQ q6mo RANKL antibody anchored by FREEDOM — with the load-bearing caveat that discontinuation causes rebound vertebral fractures and patients must transition to a bisphosphonate. Anabolic agents (teriparatide, abaloparatide, romosozumab) are reserved for severe or high-risk disease, and sequencing matters: anabolic-then-antiresorptive yields better BMD gains than the reverse order. Where the peptides in Juno's catalog actually fit: tesamorelin and B12-methylcobalamin are the two we surface here, both as honest adjuncts rather than primary treatments. Tesamorelin's GHRH-axis mechanism has positive-control data from adult GH-deficiency replacement showing BMD gains, but no fracture-outcome trial in osteoporosis populations exists — surfacing it without naming teriparatide / abaloparatide / romosozumab first would mislead. B12-methylcobalamin's case rests on the McLean 2004 + van Meurs 2004 NEJM homocysteine-fracture epidemiology plus the Sato 2005 JAMA Japanese RCT showing roughly 80% hip-fracture reduction in low-baseline post-stroke patients — established medicine for confirmed B12 deficiency, with honest acknowledgment that the strongest trial signal is single-trial and population-specific. What we don't surface: CJC-1295, BPC-157, and MK-677 all carry substrate entries for honest /ask answers when users probe, but none rises to the discovery-card threshold. CJC-1295 has zero human bone trial data and runs on the same GH-axis mechanism extrapolation as tesamorelin with weaker evidence still. BPC-157's rodent fracture-callus work is real preclinical biology but doesn't translate to human osteoporosis prevention. MK-677 has real elderly-cohort BMD-surrogate data (Murphy 2001, Nass 2008, Adunsky 2011) but no fracture-reduction signal and a problematic insulin-resistance plus edema safety profile in the elderly populations where osteoporosis matters most.